Fate Therapeutics (FATE) Stock Price
Fate Therapeutics Price
Fate Therapeutics (FATE) Stock | ISIN US31189P1021 | WKN A1W50M. The current Fate Therapeutics stock price is 1.98 USD (2026). Revenue is 5.59 M USD. Net income is -133.62 M USD. The P/E ratio is -1.76. Market capitalization is 235.2 M USD. Fate Therapeutics operates in the Health sector.
Fate Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Fate Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Fate Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Fate Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Fate Therapeutics Price |
|---|
Fate Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Fate Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Fate Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Fate Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Fate Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Fate Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Fate Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Fate Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Fate Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Fate Therapeutics business model & stock analysis
Fate Therapeutics SWOT Analysis
Strengths
Fate Therapeutics Inc demonstrates several key strengths that contribute to its competitive advantage and growth potential:
- Strong Intellectual Property Portfolio: Possesses a comprehensive patent portfolio, ensuring protection of its innovations and technologies.
- Advanced Cell Therapy Platform: Utilizes advanced cell therapy techniques, enabling the company to develop and commercialize innovative therapies for various diseases.
- Experienced Management Team: Led by a team of experienced executives and renowned scientific advisors, enhancing strategic decision-making and scientific expertise.
Weaknesses
Despite its strengths, Fate Therapeutics Inc faces certain weaknesses that could hinder its success:
- Limited Product Pipeline: Relies heavily on a few key products, making the company vulnerable to market fluctuations and regulatory challenges.
- Dependence on Partnerships: Relies on collaborations with other companies for research, development, and commercialization, increasing dependence on external entities.
- High Research and Development Costs: Incurs significant expenses in research and development activities, which could impact profitability in the short term.
Opportunities
Fate Therapeutics Inc can capitalize on several opportunities to drive its growth and market position:
- Emerging Cell Therapy Market: With the increasing demand for cell-based therapies, the company can tap into a growing market and expand its customer base.
- Expanded Applications: The innovative cell therapy platform can be applied to a wide range of diseases, offering potential for diversification and revenue expansion.
- Strategic Collaborations: By forming strategic partnerships, Fate Therapeutics Inc can leverage external expertise and resources to accelerate product development and commercialization efforts.
Threats
Fate Therapeutics Inc faces certain threats that could impact its growth and competitive position:
- Intense Competition: Faces competition from established pharmaceutical companies as well as emerging biotechnology firms, increasing the challenge of market penetration and maintaining market share.
- Regulatory Environment: The complex and evolving regulatory landscape for cell-based therapies may pose challenges in obtaining necessary approvals and complying with regulatory requirements.
- Technological Advancements: Rapid advancements in cell therapy technologies could render current products and technologies obsolete, necessitating continuous innovation and R&D investments.
Fate Therapeutics Segments
Fate Therapeutics Eulerpool Fair Value
Fate Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
Fate Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Fate Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Fate Therapeutics Earnings Estimates
Fate Therapeutics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/11/2026 | -0.29USD | 1.12 MUSD | 2026 Q1 |
| 5/6/2026 | -0.29USD | 1.12 MUSD | 2026 Q1 |
| 3/3/2026 | -0.28USD | 1.34 MUSD | 2025 Q4 |
| 3/2/2026 | -0.28USD | 1.34 MUSD | 2025 Q4 |
| 11/13/2025 | -0.3USD | 1.57 MUSD | 2025 Q3 |
| 8/11/2025 | -0.35USD | 1.03 MUSD | 2025 Q2 |
| 11/6/2024 | -0.52USD | 1.24 MUSD | 2024 Q3 |
| 5/1/2024 | -0.54USD | 1.22 MUSD | 2024 Q1 |
| 2/26/2024 | -0.53USD | 1.67 MUSD | 2023 Q4 |
| 8/1/2023 | -0.96USD | 14.21 MUSD | 2023 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Fate Therapeutics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Fate Therapeutics shareholder structure
| % | Name |
|---|---|
10.83673% | |
8.68101% | |
7.55227% | |
7.14439% | |
6.78271% | |
2.85021% | |
2.84457% | |
2.46813% | |
2.07791% | |
1.98744% |
Fate Therapeutics Executives and Management Board
Dr. Bahram Valamehr
(48)President, Chief Executive Officer, Director · since 2018
Ms. Cindy Tahl
(52)Chief Legal and Compliance Officer, Corporate Secretary
Dr. William Rastetter
(77)Independent Chairman of the Board
Dr. Karin Jooss
(60)Independent Director
Dr. Robert Epstein
(70)Independent Director
Fate Therapeutics Supply Chain
Frequently asked questions about Fate Therapeutics
The business model of Fate Therapeutics Inc revolves around the development and commercialization of cellular immunotherapies for the treatment of various diseases. The company focuses on utilizing advanced techniques to enhance the therapeutic potential of immune cells, including natural killer (NK) cells and T-cells. By engineering these cells with proprietary techniques, Fate Therapeutics aims to create more effective and targeted treatments for patients. With a strong emphasis on innovation and clinical development, Fate Therapeutics strives to bring transformative therapies to market, addressing unmet medical needs. Hamilton: Your Personal Stock Assistant
Fate Therapeutics stock
Fate Therapeutics Peer Group
Fate Therapeutics Ticker
Fate Therapeutics FIGI
All fundamentals and in-depth analysis of Fate Therapeutics
Our stock analysis for Fate Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fate Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.